EMJ Cardiology 9 [Supplement 1] . 2021

At this year’s American Heart Association (AHA) Scientific Sessions, the latest insights from clinical studies were shared to inform high-quality care by cardiologists worldwide. Dr Sheila Hegde and Dr Sara Saberi presented findings from the EXPLORER-HCM Study into the benefits of mavacamten, a first-in-class selective cardiac myosin inhibitor, on the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). Insights from these poster presentations were outlined in this article.